Zheng Wang1, Hai-Yan Song1, Meng-Meng An1, Li-Li Zhu1. 1. Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Harbin Medical University, Hormone and Endocrinology Key Laboratory of Harbin Medical University Xuefu Road 246, Harbin 150080, China.
Abstract
OBJECTIVE: To investigate the association of serum SPARC level with the severity of coronary artery lesion in type 2 diabetic patients with coronary heart disease. METHODS: 120 patients with type 2 diabetic patients were the subjects. Enzyme-linked immunosorbent assay (ELISA) was used to detect levels of serum SPARC and Gensini score was used to assess extent of coronary artery lesions. The patients were divided into 4 groups: A group was the healthy control group with 40 patients. According to angiography and the World Health Organization (WHO) diagnostic criteria for diabetes the rest were divided into B, C, D group: there were 40 cases in group B (simple type 2 diabetes mellitus group), 40 cases were in group C (simple CHD group), and 40 cases were in D group (type 2 diabetes combined with coronary heart disease group). RESULTS: Compared with that in group A, the serum SPARC level in group B, C and D increased significantly (4.22±1.19) μg/L, (3.71±1.05) μg/L and (5.96±1.40) μg/L vs (3.60±0.40) μg/L (P<0.05 ). Moreover, the serum SPARC level in group D was the highest (P<0.05). Serum SPARC level, insulin resistance (IR), and glycosylated hemoglobin (HbA1c) were the vital factors contributing to coronary heart disease. Serum SPARC level was positively correlated with the Gensini scores in group D (r=0.770, P<0.05), whereas it was not related to the Gensini scores in group C (r=0.520, P>0.05). Pearson correlation analysis showed that serum SPARC level was positively correlated with triglyceride, fasting insulin, Homeostasis Model Assessment for Insulin Resistance Index (r=0.780, 0.762 and 0.891, respectively; P<0.05). CONCLUSION: Serum SPARC level elevated in T2DM patients with coronary heart disease, which was correlated with the severity of coronary artery disease significantly.
OBJECTIVE: To investigate the association of serum SPARC level with the severity of coronary artery lesion in type 2 diabeticpatients with coronary heart disease. METHODS: 120 patients with type 2 diabeticpatients were the subjects. Enzyme-linked immunosorbent assay (ELISA) was used to detect levels of serum SPARC and Gensini score was used to assess extent of coronary artery lesions. The patients were divided into 4 groups: A group was the healthy control group with 40 patients. According to angiography and the World Health Organization (WHO) diagnostic criteria for diabetes the rest were divided into B, C, D group: there were 40 cases in group B (simple type 2 diabetes mellitus group), 40 cases were in group C (simple CHD group), and 40 cases were in D group (type 2 diabetes combined with coronary heart disease group). RESULTS: Compared with that in group A, the serum SPARC level in group B, C and D increased significantly (4.22±1.19) μg/L, (3.71±1.05) μg/L and (5.96±1.40) μg/L vs (3.60±0.40) μg/L (P<0.05 ). Moreover, the serum SPARC level in group D was the highest (P<0.05). Serum SPARC level, insulin resistance (IR), and glycosylated hemoglobin (HbA1c) were the vital factors contributing to coronary heart disease. Serum SPARC level was positively correlated with the Gensini scores in group D (r=0.770, P<0.05), whereas it was not related to the Gensini scores in group C (r=0.520, P>0.05). Pearson correlation analysis showed that serum SPARC level was positively correlated with triglyceride, fasting insulin, Homeostasis Model Assessment for Insulin Resistance Index (r=0.780, 0.762 and 0.891, respectively; P<0.05). CONCLUSION: Serum SPARC level elevated in T2DM patients with coronary heart disease, which was correlated with the severity of coronary artery disease significantly.
Entities:
Keywords:
Type 2; coronary heart disease; diabetes; secreted protein acidic and rich in cysteine
Authors: Wesam F Farrash; Bethan E Phillips; Steven L Britton; Nathan Qi; Lauren G Koch; Daniel J Wilkinson; Ken Smith; Philip J Atherton Journal: Front Endocrinol (Lausanne) Date: 2021-06-09 Impact factor: 5.555